Myriad Beats, Raises Guidance
Myriad Genetics (NASDAQ:MYGN) reported an EPS of 33 cents for the second quarter of fiscal 2012, beating both the Zacks Consensus Estimate of 31 cents and the year-ago quarter’s EPS of 26 cents. Revenues were $122.8 million, up 22% year over year and higher than the Zacks Consensus Estimate of $115 million. Myriad’s two businesses [...]
Myriad Genetics (NASDAQ:MYGN) reported an EPS of 33 cents for the second quarter of fiscal 2012, beating both the Zacks Consensus Estimate of 31 cents and the year-ago quarter’s EPS of 26 cents. Revenues were $122.8 million, up 22% year over year and higher than the Zacks Consensus Estimate of $115 million.
Myriad’s two businesses – Molecular diagnostic testing and Companion diagnostic services – recorded revenues of $117.6 million (up 17% year over year) and $5.2 million, respectively. The … [visit site to read more] or compare Credit Card Rewards and Best Credit Cards